Welcome to our dedicated page for Silo Pharma SEC filings (Ticker: SILO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Silo Pharma filings document a Nasdaq-listed Nevada operating company with common stock registered under symbol SILO and a developmental-stage biopharmaceutical business. Its registration statements and offering-related disclosures address registered securities, capital structure, smaller reporting company status, and securities transactions associated with a company developing CNS, psychiatric and chronic-pain therapeutic programs.
Recent 8-K and proxy filings record material agreements, equity issuances, shareholder voting matters, board and compensation-plan actions, and governance changes. Disclosures also cover asset purchases for QwikAgents and cryptocurrency-related software, formation of a cryptocurrency advisory board, registered and private securities transactions, and the amendment of the company’s 2020 omnibus equity incentive plan.
Silo Pharma, Inc. (SILO) entered into an asset purchase agreement with Parkview Consulting LLC on August 18, 2026 to acquire certain software, technology, domain names and related intellectual property. In exchange for these assets, Silo Pharma issued 165,000 shares of its common stock to the seller.
The issued shares are subject to a lock-up period starting on the agreement’s effective date and ending on the earlier of 12 months after that date, a defined Change in Control, or written consent of Silo Pharma. During this period, the seller is restricted from transferring or hedging the shares without Silo Pharma’s prior written consent. The agreement includes customary representations, warranties and covenants, and the seller agreed to indemnify Silo Pharma for specified misrepresentations, breaches, third‑party infringement issues and certain misconduct.
Silo Pharma, Inc. reported results of its August 14, 2026 annual shareholder meeting and a related charter change. Shareholders approved an amendment to the Articles of Incorporation to increase the number of authorized common shares from 6,666,667 to 250,000,000, and the company filed a Certificate of Amendment the same day to implement this change. Shareholders re-elected Eric Weisblum, Wayne Linsley, Kevin Muñoz, and Jeff Pavell to the board, ratified Salberg & Company, P.A. as independent registered public accounting firm for the year ending December 31, 2026, and approved an adjournment authorization proposal. A total of 697,308 common shares were represented in person or by proxy, constituting a quorum.
Silo Pharma, Inc. reported that total assets were $5.95 million at June 30, 2026, down from $7.61 million at year-end 2025, driven mainly by the use of cash for operations. Cash and cash equivalents were $3.28 million, with short-term investments of $1.95 million and crypto assets at fair value of $205,414.
For the six months ended June 30, 2026, the company generated $18,026 in license fee revenue and recorded a net loss of $2,479,946, compared with a net loss of $2,235,730 a year earlier. Research and development expenses were $1,311,683, reflecting continued investment in its psychedelic-based drug candidates and new AI-agent platform.
The company reported working capital of $4,647,793 and stated that this, together with a July 2026 private placement, mitigates prior substantial doubt about its ability to continue as a going concern. Shares outstanding were 1,128,610 at June 30, 2026 and 1,588,250 as of August 13, 2026, following equity issuances and a 1‑for‑15 reverse stock split effective June 2026.
Intracoastal Capital LLC and its principals report a significant ownership position in Silo Pharma, Inc. As of June 30, 2026, Mitchell P. Kopin, Daniel B. Asher and Intracoastal collectively report beneficial ownership of 125,261 shares of Silo common stock, representing 9.99% of the outstanding common stock. This stake is entirely issuable upon exercise of five warrants held by Intracoastal, with 125,261 shares from three warrants counted toward current beneficial ownership and additional shares from two warrants and part of a third excluded by blocker provisions that cap ownership at 9.99% or 4.99%. Without these blocker provisions, the reporting group indicates they could be deemed to beneficially own 222,995 shares. All voting and dispositive powers over the reported shares are shared, with no sole authority reported by any of the filers.
Silo Pharma, Inc. is registering for resale up to 1,906,392 shares of common stock held by selling shareholders. The registered shares comprise 124,000 already issued shares and shares issuable upon exercise of pre-funded, Series A-3, Series A-4 and placement agent warrants issued in a July 2026 private placement.
This is a resale registration; the company states it will not receive proceeds from share sales by the selling shareholders. It may receive cash only if the warrants associated with 1,782,392 of the registered shares are exercised, in which case it would receive the stated exercise prices. Following full cash exercise of those warrants, shares outstanding would be 3,035,002.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency company, with lead drug candidate SPC-15 for PTSD and anxiety, plus additional preclinical programs for fibromyalgia, Alzheimer’s disease and CNS disorders. In June 2026 it completed a 1-for-15 reverse stock split, leaving 6,666,667 authorized common shares. The company reported a 2025 net loss of $4,227,698 and held $173,462 of crypto assets at fair value as of March 31, 2026.
Silo Pharma, Inc., a Nevada-based diversified developmental-stage biopharmaceutical and cryptocurrency company, has filed to register for resale up to 1,906,392 shares of common stock held by selling shareholders. The shares consist of 124,000 common shares issued in a July 2026 private placement and 1,782,392 shares issuable upon exercise of pre-funded, Series A-3, Series A-4 and placement agent warrants. This is a resale registration; the company will not receive proceeds from any sale of shares by selling holders.
The warrants are immediately exercisable at prices of $0.0001 (pre-funded), $6.21 (Series A-3 and A-4) and $8.065 (placement agent), with expirations ranging from 18 months to five years after effectiveness and subject to 4.99% or 9.99% beneficial ownership limits. If all 1,782,392 warrant shares registered here are exercised for cash, Silo estimates gross proceeds of approximately $8.07 million, intended for working capital and general corporate purposes. Assuming full cash exercise, common shares outstanding would be 3,035,002. Silo recently effected a 1-for-15 reverse stock split, reducing authorized common stock to 6,666,667 shares, and reported a 2025 net loss of $4,227,698 and a first-quarter 2026 net loss of $1,647,117. The company’s pipeline includes intranasal PTSD and Alzheimer’s candidates, a ketamine implant for fibromyalgia, and CNS peptide technology, alongside a crypto-asset treasury and staking strategy.
Silo Pharma, Inc., a Nevada biotechnology corporation based in Sarasota, Florida, conducted an exempt private securities offering in reliance on Rule 506(b). The company reported a total amount sold of $4,000,015 and a total remaining to be sold of $0.
H.C. Wainwright & Co., LLC acted as placement agent and received $300,002 in cash commissions plus warrants to purchase up to 46,497 shares of common stock at an exercise price of $8.065 per share. The initial sale in this offering occurred on July 9, 2026.
Silo Pharma, Inc. entered into securities purchase agreements with institutional investors for a private placement of its equity and warrants. The structure includes 124,000 shares of common stock at $6.452 per share and pre-funded warrants to purchase up to 495,965 shares of common stock at $6.4519 per warrant, together covering 619,965 shares. Investors also received Series A-3 and Series A-4 warrants to purchase up to 619,965 shares each, all with an exercise price of $6.21 per share, exercisable immediately, with expirations five years and eighteen months, respectively, after the effective date of a resale registration statement. Silo expects aggregate gross proceeds of about $4 million and net proceeds of approximately $3.5 million, and may receive up to roughly $7.7 million in additional gross proceeds if all warrants are exercised for cash. H.C. Wainwright & Co. acted as exclusive placement agent and received a cash fee and warrants for 46,497 shares at an exercise price of $8.065. Net proceeds are intended for working capital and general corporate purposes.
AdvisorShares Trust filed a Schedule 13G reporting beneficial ownership of 6.69% of Silo Pharma, Inc. The filing shows 75,582 shares of common stock (CUSIP 82711P300) as beneficially owned as of 06/30/2026. The report is signed by Stefanie Little, Chief Compliance Officer, on 07/08/2026.